GAB2在卵巢癌组织中的表达及其与预后的相关性

doi:10.11904/j.issn.1002-3070.2022.02.009

Abstract

Abstract: Objective The aim of this study was to evaluate the expression of Grb-associated binding protein 2(GAB2)in patients with ovarian cancer and its relationship with prognosis.Methods A total of 119 ovarian cancer tissues and adjacent tissues were collected from The Affiliated Tumor Hospital of Nantong University from January 2013 to January 2016.The expression of GAB2 in the tissues was detected by immunohistochemical staining,and its correlation with clinical characteristics was analyzed.The relationship between GAB2 expression and survival was analyzed by Kaplan-Meier survival curve.Cox proportional hazard regression model was used to analyze the risk factors affecting the prognosis of ovarian cancer patients.Finally,a Nomogram prognosis model was constructed to predict 3-year and 5-year survival rates of ovarian cancer patients based on Cox proportional hazard regression model.Results Compared with adjacent tissue,the expression of GAB2 was increased in tumor tissues(P＜0.001).In addition,the level of GAB2 was significantly correlated with FIGO stage(P=0.004),the level of CA125 at initial diagnosis(P=0.005),and platinum-resistant recurrence(P＜0.001).Kaplan-Meier curves showed that the high expression of GAB2 was associated with the decrease of OS(P＜0.001).Univariate analysis showed that the level of GAB2,FIGO stage,CA125 level at initial diagnosis and platinum-resistant recurrence were associated with OS in ovarian cancer patients(P＜0.05).Multivariate analysis showed that GAB2 expression was an independent factor affecting the prognosis of ovarian cancer patients.The Nomogram prognostic model had good predictive power for 3-year and 5-year survival in ovarian cancer patients,with a C-index of 0.801.Conclusion The expression of GAB2 can predict the prognosis of ovarian cancer patients,and is expected to be a potential target for ovarian cancer treatment

Key words: Ovarian cancer, Grb-associated binding protein 2, Prognosis

CLC Number:

R711.75

YIN Yi, OU Chaoyang, HE Aiqin. Expression of GAB2 in ovarian cancer and its correlation with prognosis[J]. Journal of Practical Oncology, 2022, 36(2): 150-155.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/10.11904/j.issn.1002-3070.2022.02.009

http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/Y2022/V36/I2/150

References

1 Momenimovahed Z,Tiznobaik A,Taheri S,et al.Ovarian cancer in the world:epidemiology and risk factors[J].Int J Womens Health,2019,11(1):287-299.
2 Torre LA,Trabert B,DeSantis CE,et al.Ovarian cancer statistics,2018[J].CA Cancer J Clin,2018,68(4):284-296.
3 Fitzmaurice C,Dicker D.The global burden of cancer 2013:global burden of disease cancer collaboration[J].JAMA Oncol,2015,1(4):505-527.
4 Narod S.Can advanced-stage ovarian cancer be cured?[J].Nat Rev Clin Oncol,2016,13(4):255-261.
5 孙帅.吉西他滨联合顺铂治疗晚期复发性卵巢癌 18 例疗效观察[J].肿瘤学杂志,2018,24(9):896-899.
6 Zhang W,Samelson LE.The role of membrane-associated adaptors in T cell receptor signalling[J].Semin Immunol,2000,12(1):35-41.
7 Gu H,Neel BG.The“Gab”in signal transduction[J].Trends Cell Biol,2003,13(3):122-130.
8 Brummer T,Schramek D,Hayes VM,et al.Increased proliferation and altered growth factor dependence of human mammary epithelial cells overexpressing the GAB2 docking protein[J].J Biol Chem,2006,281(1):626-637.
9 Huang E,Cheng SH,Dressman H,et al.Gene expression predictors of breast cancer outcomes[J].Lancet,2003,361(9369):1590-1596.
10 Herrera Abreu MT,Hughes WE,Mele K,et al.GAB2 regulates cytoskeletal organization and migration of mammary epithelial cells by modulating RhoA activation[J].Mol Biol Cell,2011,22(1):105-116.
11 Dunn GP,Cheung HW,Agarwalla PK,et al.In vivo multiplexed interrogation of amplified genes identifies GAB2 as an ovarian cancer oncogene[J].Proc Natl Acad Sci U S A,2014,111(3):1102-1107.
12 Liu X,Wu A,Wang X,et al.Identification of metabolism-associated molecular subtype in ovarian cancer[J].J Cell Mol Med,2021,25(20):9617-9626.
13 李委佳,贾朝阳,冯书君,等.NDRG4通过Wnt/β-catenin信号转导通路抑制卵巢癌细胞的迁移和侵袭能力[J].实用肿瘤杂志,2019,34(6):497-502.
14 Yamada K,Nishida K,Hibi M,et al.Comparative FISH mapping of GAB1 and GAB2 genes in human,mouse and rat[J].Cytogenet Cell Genet,2001,94(1/2):39-42.
15 Sun B,Jensen NR,Chung D,et al.Synergistic effects of SHP2 and PI3K pathway inhibitors in GAB2-overexpressing ovarian cancer[J].Am J Cancer Res,2019,9(1):145-159.
16 Bunda S,Burrell K,Heir P,et al.Inhibition of SHP2-mediated dephosphorylation of Ras suppresses oncogenesis[J].Nat Commun,2015,6(1):8859.
17 Zhang X,Dong Z,Zhang C,et al.Critical role for GAB2 in neuroblastoma pathogenesis through the promotion of SHP2/MYCN cooperation[J].Cell Rep,2017,18(12):2932-2942.
18 Cheng Z,Sun W,Ni X,et al.GAB2 inhibits chondrocyte apoptosis through PI3K-AKT signaling in osteoarthritis[J].Int J Clin Exp Pathol,2020,13(3):616-623.
19 Tian J,Zhang H,Mu L,et al.The miR-218/GAB2 axis regulates proliferation,invasion and EMT via the PI3K/AKT/GSK-3β pathway in prostate cancer[J].Exp Cell Res,2020,394(1):112128.
20 Ding C,Luo J,Fan X,et al.Elevated GAB2 induces tumor growth and angiogenesis in colorectal cancer through upregulating VEGF levels[J].J Exp Clin Cancer Res,2017,36(1):56.
21 Duckworth C,Zhang L,Carroll SL,et al.Overexpression of GAB2 in ovarian cancer cells promotes tumor growth and angiogenesis by upregulating chemokine expression[J].Oncogene,2016,35(31):4036-4047.
22 Berkel C,Cacan E.GAB2 and GAB3 are expressed in a tumor stage-,grade-and histotype-dependent manner and are associated with shorter progression-free survival in ovarian cancer[J].J Cell Commun Signal,2021,15(1):57-70.

[1]	WANG Hongying, LI Yan, HAN Xinhao, WEI Xiaoli, JIA Huixun, YUAN Wenjuan, ZHANG Qiuju. Construction and validation of a risk model for early diagnosis and prognosis of gastric cancer based on immune-related lncRNAs [J]. Journal of Practical Oncology, 2022, 36(2): 119-126.
[2]	LI Weihua, ZHANG Guangfeng, MA Lili, HE Pin, WANG Wen, LI Dingfu. Construction of a breast cancer prognostic model based on metabolism-related genes in the TCGA database [J]. Journal of Practical Oncology, 2022, 36(1): 37-43.
[3]	WANG Yuping, SI Meili, SUN Xiaoxia, GUO Yulin. High expression of HPIP in endometrial carcinoma and its significance in the analysis of survival and prognosis [J]. Journal of Practical Oncology, 2022, 36(1): 44-48.
[4]	DONG Lina, LIANG Tian, ZHANG Xian, ZHANG Guangmei. Research progress on tropism of ovarian cancer to fat-rich omentum organs [J]. Journal of Practical Oncology, 2022, 36(1): 54-58.
[5]	CAO Shiyu, JIANG Yongdong. The influence of gene expression,polygene detection and biomarkers on the prognosis of Luminal A-like breast cancer [J]. Journal of Practical Oncology, 2022, 36(1): 89-93.
[6]	WANG Lina, WANG Le, JIN Hong, LI Qi, CHENG Haiyan. The expression of UBQLN1 in cervical cancer and its effect on prognosis [J]. Journal of Practical Oncology, 2021, 35(6): 506-510.
[7]	CHEN Yixin, SUN Yihua, CHENG Yangyang, HE Kaitong, GUO Ting. Relationship between preoperative inflammation-related indicators and prognosis of patients with resectable gastric cancer [J]. Journal of Practical Oncology, 2021, 35(6): 517-522.
[8]	LU Junrong, WANG Huiwen, HE Dongfeng. Significance of high expression of SALL4 in clinicopathological and prognostic judgment of esophageal squamous cell carcinoma [J]. Journal of Practical Oncology, 2021, 35(5): 420-425.
[9]	YU Youlin, YU Junlin, HU Chaohua, SHEN Xiongshan, LI Weimin, LU Ting, YANG Feng, YANG Qingqing, LIU Chenhao. Analysis for clinical prognostic value of LAYN in thyroid cancer and its influence on infiltration of immune cells [J]. Journal of Practical Oncology, 2021, 35(4): 357-364.
[10]	LIU Wen, QIAO Wenbo. Clinical research status of programmed cell death protein-1 and its ligand in colorectal cancer [J]. Journal of Practical Oncology, 2021, 35(4): 370-375.
[11]	DONG Xiaoping, ZHANG Xue, GUO Dongli, HE Yutong. Research progress on the related factors affecting the prognosis of squamous cell carcinoma of lung [J]. Journal of Practical Oncology, 2021, 35(4): 380-385.
[12]	YIN Lei, YANG Xudong, YANG Yue, NIU Xingjian, ZHOU Xiaoping, JI Hongfei, WANG Yiran. The clinical significance and related mechanism of neutrophil to lymphocyte ratio in the prognostic evaluation of patients with non small cell lung cancer [J]. Journal of Practical Oncology, 2021, 35(2): 117-124.
[13]	BI Jiaqing, QIN Qian, MA Huihan, MA Meijie, FENG Qinmei. Research progress of threonine and tyrosine kinase in tumor [J]. Journal of Practical Oncology, 2021, 35(2): 188-192.
[14]	ZHANG Lu,LU Jingyu,LU Haijun. The relationship between biomarkers of head and neck squamous cell carcinoma and prognosis of immunotherapy [J]. Journal of Practical Oncology, 2021, 35(1): 55-58.
[15]	ZHANG Wenwen,JIANG Liangliang,WANG Jing. Application prospect of CAR-T therapy in ovarian cancer [J]. Journal of Practical Oncology, 2021, 35(1): 59-63.

Expression of GAB2 in ovarian cancer and its correlation with prognosis

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments